Shah, A. N., Flaum, L., Helenowski, I., Santa-Maria, C. A., Jain, S., Rademaker, A., . . . Gradishar, W. (2020). Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer. J Immunother Cancer.
Chicago Style CitationShah, Ami N., et al. "Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-positive, HER2−negative Endocrine-refractory Metastatic Breast Cancer." J Immunother Cancer 2020.
Cita MLAShah, Ami N., et al. "Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-positive, HER2−negative Endocrine-refractory Metastatic Breast Cancer." J Immunother Cancer 2020.